The Combination of the PARP Inhibitor Olaparib and the ATR Inhibitor VE-821 Selectively Targets ATM-Deficient Lung Cancer Cells

被引：0
|
作者：
Jette, N. [1 ]
Radhamani, S. [1 ]
Arthur, G. [1 ]
Ye, R. [1 ]
Goutam, S. [1 ]
Boylos, A. [1 ]
Petersen, L. [1 ]
Bose, P. [1 ]
Bebb, G. [1 ]
Lees-Miller, S. [1 ]
机构：
[1] Univ Calgary, Calgary, AB, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Olaparib; VE-821; ATM;
D O I：
10.1016/j.jtho.2019.08.1192
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.14-41
引用
收藏
页码：S570 / S571
页数：2
相关论文
共 50 条
  • [1] Preclinical evaluation of the ATR inhibitor VE-821 alone and in combination with the PARP inhibitor olaparib in neuroblastoma
    Southgate, H.
    Chen, L.
    Curtin, N. J.
    Tweddle, D. A.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E31 - E31
  • [2] ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib
    Wang, Chen
    Jette, Nicholas
    Moussienko, Daniel
    Bebb, D. Gwyn
    Lees-Miller, Susan P.
    TRANSLATIONAL ONCOLOGY, 2017, 10 (02): : 190 - 196
  • [3] The combination of the PARP inhibitor talazoparib (BMN 673) with the ATR inhibitor VE-821 overcomes the drug resistance of Schlafen 11-deficient cells
    Murai, Junko
    Pommier, Yves
    CANCER RESEARCH, 2015, 75
  • [4] The novel ATR inhibitor VE-821 selectively sensitizes pancreatic cancer cells to radiation and chemotherapy
    Fokas, E.
    Prevo, R.
    Reaper, P.
    Charlton, P.
    Pollard, J.
    McKenna, W. G.
    Muschel, R.
    Brunner, T.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 : 115 - 116
  • [5] ATM-deficient lung, prostate and pancreatic cancer cells are acutely sensitive to the combination of olaparib and the ATR inhibitor AZD6738
    Nicholas R. Jette
    Suraj Radhamani
    Ruiqiong Ye
    Yaping Yu
    Greydon Arthur
    Siddhartha Goutam
    Tarek A. Bismar
    Mehul Kumar
    Pinaki Bose
    Steven Yip
    Michael Kolinsky
    Susan P. Lees-Miller
    Genome Instability & Disease, 2020, 1 (4) : 197 - 205
  • [6] The ATR inhibitor VE-821 increases the sensitivity of gastric cancer cells to cisplatin
    Su, Haochen
    Yuan, Yue
    Tang, Jiatong
    Zhang, Yixuan
    Wu, Hao
    Zhang, Yin
    Liang, Jiawei
    Wang, Lei
    Zou, Xiaoping
    Huang, Shuling
    Zhang, Shu
    Lv, Ying
    TRANSLATIONAL ONCOLOGY, 2023, 36
  • [7] The PARP inhibitor olaparib is synergistic with the ATR inhibitor AZD6738 in ATM deficient cancer cells
    Lloyd, Rebecca
    Falenta, Katarynza
    Wijnhoven, Paul W.
    Chabbert, Christophe
    Stott, Jonathan
    Yates, James
    Lau, Alan Y.
    Young, Lucy A.
    Hollingsworth, Simon J.
    CANCER RESEARCH, 2018, 78 (13)
  • [8] Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821
    Colis, Laureen C.
    Herzon, Seth B.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (13) : 3122 - 3126
  • [9] Activity of the PARP inhibitor olaparib in ATM-deficient gastric cancer: from preclinical models to the clinic
    Hodgson, Darren
    Mason, Helen
    Oplustilova, Lenka
    Harbron, Chris
    Yin, Xiaolu
    Im, Seock-Ah
    Jones, Helen
    Lai Zhongwu
    Dougherty, Brian
    McLoughlin, Matthew
    Bradford, James
    Dickinson, Andrew
    Fielding, Anitra
    Robertson, Jane
    Kim, Woo-Ho
    Womack, Chris
    Gu, Yi
    Bang, Yung-Jue
    Lau, Alan
    Barrett, J. Carl
    O'Connor, Mark J.
    CANCER RESEARCH, 2014, 74 (19)
  • [10] The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy
    Prevo, Remko
    Fokas, Emmanouil
    Reaper, Philip M.
    Charlton, Peter A.
    Pollard, John R.
    McKenna, W. Gillies
    Muschel, Ruth J.
    Brunner, Thomas B.
    CANCER BIOLOGY & THERAPY, 2012, 13 (11) : 1072 - 1081
12345